A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3

Inclusion Criteria Concurrent Medication: Allowed: * Antiretroviral therapy. * Macrolides for disseminated Mycobacterium avium. * Atovaquone for toxoplasmosis. * Other antimicrobials for concurrent infections. * Lomotil, Imodium, or deodorized opium tincture in a standardized regimen for diarrhea. Patients must have: * Advanced HIV disease. * Diarrhea presumptively caused by Cryptosporidia. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Hypersensitivity to aminoglycosides. * Inability to swallow capsules. * Active infection due to other enteric pathogens. Previous diagnosis of CMV or MAC infection permitted if patient is currently stabilized on a therapeutic regimen (clarithromycin up to 500 mg bid or azithromycin up to 600 mg daily). * Other known causes for diarrhea (e.g., malabsorption syndrome, gastrointestinal Kaposi's sarcoma). Concurrent Medication: Excluded during the first 9 weeks of study: * Agents with putative anticryptosporidial activity (such as spiramycin, diclazuril, letrazuril, or bovine colostrum). * Octreotide acetate (Sandostatin). * Antidiarrheals other than those specifically allowed. * Clarithromycin if initiated at 500 mg or higher or azithromycin if initiated at 600 mg or higher. Prior Medication: Excluded: * Paromomycin at \> 1 g/day for \>= 14 days prior to study entry. Excluded within 14 days prior to study entry: * Agents with putative anticryptosporidial activity (such as spiramycin, diclazuril, letrazuril, or bovine colostrum), with the exception of macrolides that are permitted for other indications. * Octreotide acetate (Sandostatin).